Int J Radiat Oncol Biol Phys 2021 Dec 1
Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy.
Related Questions
New comment by Radiation Oncologist at Mayo Clinic College of Medicine and Science (Jacksonville) ( December 13, 2023)
There is only 20-30% rate of spontaneous conversion of day+30 PR to CR without additional therapies. This means that the majority progress. In our study (Saifi et al., PMID 37...
New answer by Radiation Oncologist at Mayo Clinic (October 24, 2023)
Before answering this important question, I think that we, as Radiation Oncologists, should give serious consideration to moving past the terminology of "bridging radiation th...
New answer by Medical Oncologist at Memorial Sloan Kettering Cancer Center (November 15, 2023)
Chimeric antigen receptor (CAR) T-cell therapy has been approved by the US Food and Drug Administration and other regulatory agencies for patients with R/R DLBCL (including hi...